Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue

Gossamer Bio, Inc (NASDAQ:GOSS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. Gossamer Bio, Inc (NASDAQ:GOSS) reported its fourth-quarter results on March 17, delivering a mixed performance as earnings missed expectations while revenue came in stronger than expected. The company posted a GAAP loss of $0.21 per share, falling short of estimates by $0.02 per share. On the revenue side, sales reached $13.8 million, representing a 47.8% year-over-year increase. The figure beat consensus estimates by $6.28 million, indicating a solid top-line growth despite the earnings shortfall.

Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple

Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio, Inc (NASDAQ:GOSS) commented:

“Following our PROSERA topline results, we are focused on fully understanding the PROSERA dataset, engaging with the FDA, and evaluating strategic options and capital allocation to position the Company for the future. PROSERA narrowly missed the prespecified statistical threshold for its primary endpoint; however, we believe the totality of evidence supports that seralutinib is an active drug in PAH, with the most pronounced effects observed in patients with more advanced disease.”

On March 6, H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Gossamer Bio Inc (NASDAQ:GOSS) from $10 to $5 while maintaining a Buy rating. The price target adjustment follows a change in the firm’s outlook for seralutinib in pulmonary arterial hypertension. The analyst lowered the estimated probability of success for the drug to 50%, down from the previous 70%, which resulted in the revised valuation and lower price target.

Gossamer Bio, Inc (NASDAQ:GOSS) is a pharmaceutical company specializing in the discovery, development, and marketing of treatments in the medical fields of immunology, inflammation, and oncology.

While we acknowledge the risk and potential of GOSS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GOSS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.